Paula Green Sells 294 Shares of Twist Bioscience (NASDAQ:TWST) Stock

Key Points

• Paula Green sold 294 Twist Bioscience shares at an average price of $165.49, generating $48,654.06. The sale covered tax-withholding obligations, and she retained 116,720 shares.
• Twist Bioscience shares fell 3.7% to $158.50, despite quarterly revenue rising 23.2% year over year to $118.38 million. The company missed analysts’ earnings estimate, reporting a loss of $0.56 per share versus expectations of $0.51.
• Analyst sentiment remains a Moderate Buy, with eight Buy, two Hold and two Sell ratings; recent price targets ranged from $102 to $160, while the consensus target was $103.

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) SVP Paula Green sold 294 shares of the stock in a transaction on Monday, September 21st. The stock was sold at an average price of $165.49, for a total transaction of $48,654.06. Following the transaction, the senior vice president directly owned 116,720 shares in the company, valued at approximately $19,315,992.80. This represents a 0.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Twist Bioscience Stock Down 3.7%

NASDAQ:TWST traded down $6.10 during trading hours on Wednesday, reaching $158.50. The company had a trading volume of 2,133,311 shares, compared to its average volume of 1,563,605. Twist Bioscience Corporation has a twelve month low of $23.30 and a twelve month high of $170.66. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03. The firm has a market cap of $9.94 billion, a price-to-earnings ratio of -71.40 and a beta of 2.22. The business's 50-day simple moving average is $121.94 and its two-hundred day simple moving average is $84.72.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.05). The company had revenue of $118.38 million for the quarter, compared to analyst estimates of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. Twist Bioscience's revenue for the quarter was up 23.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.33 EPS. On average, equities analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Institutional Investors Weigh In On Twist Bioscience

A number of institutional investors and hedge funds have recently bought and sold shares of TWST. Engineers Gate Manager LP bought a new position in Twist Bioscience during the 2nd quarter valued at $3,333,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Twist Bioscience in the second quarter valued at about $99,000. Allworth Financial LP lifted its position in shares of Twist Bioscience by 54.9% during the second quarter. Allworth Financial LP now owns 601 shares of the company's stock valued at $62,000 after purchasing an additional 213 shares in the last quarter. Nykredit A S bought a new position in shares of Twist Bioscience during the second quarter valued at about $283,000. Finally, Allianz Asset Management GmbH purchased a new position in Twist Bioscience during the second quarter worth about $1,327,000.

Analyst Upgrades and Downgrades

TWST has been the subject of a number of research reports. Evercore cut Twist Bioscience from an "outperform" rating to an "in-line" rating and set a $102.00 price objective for the company. in a research note on Monday, July 6th. Piper Sandler upped their target price on Twist Bioscience from $85.00 to $115.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 5th. Weiss Ratings reissued a "sell (d-)" rating on shares of Twist Bioscience in a research report on Monday. Canaccord Genuity Group boosted their price target on shares of Twist Bioscience from $90.00 to $120.00 and gave the company a "buy" rating in a research note on Tuesday, July 14th. Finally, Leerink Partners boosted their price target on shares of Twist Bioscience from $120.00 to $160.00 and gave the company an "outperform" rating in a research note on Thursday, September 17th. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Twist Bioscience has an average rating of "Moderate Buy" and a consensus price target of $103.00.

About Twist Bioscience

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA using a proprietary silicon-based platform. The company serves researchers and organizations in biotechnology, pharmaceutical development, agriculture, industrial chemicals and academic research.

Its products include synthetic genes, gene fragments, oligonucleotides and DNA libraries used in research, drug discovery, diagnostics development and other applications. Twist also provides next-generation sequencing tools and products, including target-enrichment and sample-preparation solutions, as well as synthetic biology services that support the design and testing of biological systems.

Twist was founded in 2013 and is headquartered in South San Francisco, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.